Market Snapshot
S&P Futures
3,814.5
Dow Futures
30,961
Nasdaq Futures
11,557.75
Kura Oncology, Inc. (KURA) stock rallied over 0.93% intraday to trade at $18.50 a share on NASDAQ. The stock opened with a gain of 2.72% at $18.41 and touched an intraday high of $19.179, rising 0.93% against the last close of $18.33. The stock went to a low of $17.83 during the session.
Prev. Close
Market Cap
Day Low
Open
Number of Shares
Day High
P/E ratio
EPS (TTM)
Cash Flow per Share
Free Float in %
Book Value
Volume
Date | Open | High | Low | Close | Volume |
---|---|---|---|---|---|
2022-07-01 | $18.41 | $19.179 | $17.83 | $18.5 | 775,400 |
2022-06-30 | $18.01 | $18.63 | $17.85 | $18.33 | 486,400 |
2022-06-29 | $17.34 | $18.36 | $17.15 | $18.22 | 526,600 |
2022-06-28 | $17.38 | $17.82 | $16.85 | $17.46 | 824,000 |
2022-06-27 | $18.15 | $18.34 | $17.23 | $17.35 | 916,600 |
2022-06-24 | $17.33 | $18.35 | $16.81 | $18.17 | 1,491,900 |
2022-06-23 | $16.14 | $17.3 | $15.92 | $17.21 | 763,000 |
2022-06-22 | $14.59 | $16.32 | $14.52 | $16.07 | 944,600 |
2022-06-21 | $14.21 | $15.41 | $14.21 | $14.84 | 690,200 |
2022-06-17 | $13.63 | $14.26 | $13.45 | $14.21 | 1,791,400 |
Employees-
Beta1.07
Sales or Revenue0
5Y Sales Change-
Fiscal Year Ends2021-12-30
SectorHealth Care
IndustryBiotechnology
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, a small molecule inhibitor of the menin-Lysine K-specific Methyltransferase 2A protein-protein interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; and tipifarnib, an orally bioavailable inhibitor of farnesyl transferase that is in Phase II clinical trials for the treatment of solid tumors and hematologic indications. The company has a clinical collaboration with Novartis to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression or PIK3CA mutation and/or amplification. Kura Oncology, Inc. was founded in 2014 and is headquartered in San Diego, California.
Kura Oncology, Inc. (NASDAQ: KURA) stock price is $18.5 as of the last check on Friday, July 1. During the trading session, KURA stock reached the peak price of $19.179 while $17.83 was the lowest point it dropped to.
The NASDAQ listed KURA is part of Biotechnology industry that operates in the broader Health Care sector. Kura Oncology, Inc. , a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States.
Dr. Troy Edward Wilson
Chairman, CEO & Pres
Dr. Marc Grasso
CFO & Chief Bus. Officer
Mr. Pete De Spain
VP of Investor Relations & Corp. Communications
Dr. Nic G. Scalfarotto
Sr. VP of Regulatory Affairs
KURA stock traded closed the last session at $18.5, which is $0.17 or 0.93% lower than its previous close of $18.33. KURA's current trading price is 77.71% lower than its 52-week high of $22.03 where as its distance from 52-week low of 10.41% is -16.02%.
Number of KURA employees currently stands at -. KURA operates from 12730 High Bluff Drive, Suite 400, San Diego, CA 92130, United States.
Official Webiste of $KURA is: https://kuraoncology.com
KURA could be contacted at KURA operates from 12730 High Bluff Drive, Suite 400, San Diego, CA 92130, United States, or at phone #858 500 8800 and can also be accessed through its website.
KURA stock volume for the day was 771,385 shares while in the previous session number of KURA shares traded was 775,400 . The average number of KURA shares traded daily for last 3 months was 627.81 Thousands.
The percentage change in KURA stock occurred in the recent session was 0.93% while the dollar amount for the price change in KURA stock was $0.17.
In the recent session, the day high for KURA stock was $19.179 while the low for KURA stock touched on the day was $17.83.
The market value of KURA currently stands at 1.22 Billion with its latest stock price at $18.5 and 66.61 Million of its shares outstanding.